BridgeBio (BBIO) announced that 18-month results from PROPEL 2, a Phase 2 trial of the investigational therapy infigratinib in children with achondroplasia, were published as an original research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback